The level of some hematologic indicators of the systemic inflammatory response as an indicator of the state of the oncourological patients
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Materials and methods. To achieve the goal of the study, data from the case histories of 830 patients were distributed to 4 groups. Group I – 717 patients with genitourinary cancer who require special treatment. Group II – 35 people without oncological and other pathology. Group III – 38 patients with benign tumors / conditions of urogenital organs. Group IV – 40 cancer patients who underwent radical special treatment, and who did not show any signs of illness. Patients with leukemia, acute inflammatory processes after special treatment, who were urgently hospitalized in the department for symptomatic treatment, and patients with significant deviations in the parameters of the general blood test after a recent polychemotherapy were excluded from the study.
Results. The results of the study indicate that both absolute and relative mean lymphocyte counts in peripheral blood significantly differ among patients of different groups. So, the absolute level of lymphocytes is the worst in cancer patients of urological organs in comparison with radically treated, healthy and sick with benign tumors. The worst relative level of blood lymphocytes was detected in oncourological patients who need treatment, in contrast to radically treated, healthy
and patients with benign tumors of urological organs.
Conclusion. The results of the leukogram are a simple available laboratory indicator that provides important prognostic information about the condition of the disease, and indirectly about the state of its systemic inflammatory response, which is an essential pathogenetic factor in the development and progression of cancer. Therapeutic measures that promote the growth of the absolute and relative level of blood lymphocytes of the patient can be considered as those that positively
pathogenetically affect the condition of the oncourological patient and require further detailed study.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Atzpodien J. Metastatic renal carcinoma comprehensive prognostic system / Atzpodien J., Royston P., Wandert T. et al. // Br J Cancer. – 2003. – 88. – P. 348–53.
Bruckner H.W. Absolute granulocyte, lymphocyte, and monocyte counts. Useful determinants of prognosis for patients with metastatic cancer of the stomach / Bruckner H.W., Lavin P.T., Plaxe S.C. et al. // JAMA. – 1982. – 247. – P. 1004–6.
Eggener S.E. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence / Eggener S.E., Yossepowitch O., Pettus J.A. et al. // J Clin Oncol. – 2006. – 24. – P. 3101–6.
Fahn H.J. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma / Fahn H.J., Lee Y.H., Chen M.T. et al. // J Urol – 1991. – 145. – P. 248–50.
Fumagalli L.A. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy / Fumagalli L.A., Vinke J., Hoff W. et al. // J Immunother. – 2003. – 26. – P. 394–402.
Gakis G. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score / Gakis G., Todenhöfer T., Renninger M. et al. // BJU International. – 2011. – 108 (11). – P. 1800–1805.
Grivennikov S. Immunity, Inflammation, and Cancer / Grivennikov S., Greten F.R., Karin M. // Cell – 2010. – 140 (6). – P. 883–899.
Hanahan D. Hallmarks of cancer: the next generation / Hanahan D., Weinberg R.A. // Cell. – 2011. – 144 (5). – P. 646–74.
Jeong I.G. Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival / Jeong I.G., Han K.S., Joung J.Y. et al. // J Korean Med Sci. – 2007. – 22 suppl. – S122–8.
Kim H.S. Systemic Inflammatory Response Based on Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker in Bladder Cancer / Kim H.S., Ku J.H. // Dis Markers. – 2016. – Article ID 8345286. – P. 1–12.
Mano R. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer / Mano R., Baniel J., Shoshany O. // Urol Oncol. – 2015. – 33 (2):67. – P. e1-7.
Morgan T.M. Editorial Comment to: Saroha S. Lymphopenia is an Independent Predictor of Inferior Outcome in Clear Cell Renal Carcinoma / Saroha S, Uzzo R.G., Plimack E.R., et al. // J Urol. – 2013. – 189 (2): p. 460.
Motzer R.J. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma / Motzer R.J., Bacik J., Schwartz L.H. et al. // J Clin Oncol. – 2004. – 22. – P. 454–63.
Ohno Y. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma / Ohno Y., Nakashima J., Ohori M. et al.// J Urol. – 2010. – 184. – P. 873–8.
Ozyalvacli M.E. Neutrophil-lymphocyte ratio as a predictor of recurrence and progression in patients with high-grade pT1 bladder cancer / Ozyalvacli M.E., Ozyalvacli G., Kocaaslan R. et al. / Can Urol Assoc J. – 2015. – 9 (3–4). – P. E126-31.
Ramsey S. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer / Ramsey S., Lamb G.W., Aitchison M. et al. // Cancer. – 2007. – 109. – P. 205–12.
Saroha S. Lymphopenia is an Independent Predictor of Inferior Outcome in Clear Cell Renal Carcinoma / Saroha S., Uzzo R.G., Plimack E.R., et al. // J Urol. – 2013. – 189 (2). – P. 454–460.
Suppiah R. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma / Suppiah R., Shaheen P.E., Elson P. et al. // Cancer. – 2006. – 107. – P. 1793–800.
Sylvester R.J. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. / Sylvester R.J., van der Meijden A.P., Oosterlinck W. et al. // Eur Urol – 2006. – 49. – P. 466–75.
Viers B.R. Pretreatment neutrophilto-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy / Viers B.R., Boorjian S.A., Frank I. et al. //Eur Urol. – 2014. – 66 (6). – P. 1157–64.
